TG Therapeutics challenges Roche with FDA filing for CLL drugUS biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic Share XTG Therapeutics challenges Roche with FDA filing for CLL drughttps://pharmaphorum.com/news/tg-therapeutics-challenges-roche-with-fda-filing-for-cll-drug/
ADC Therapeutics sets terms for $125m IPOSwiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop Share XADC Therapeutics sets terms for $125m IPOhttps://pharmaphorum.com/news/adc-therapeutics-sets-terms-for-125m-ipo/
Concerns over BMS and Celgene merger payout as FDA extends drug reviewBristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be Share XConcerns over BMS and Celgene merger payout as FDA extends drug reviewhttps://pharmaphorum.com/news/concerns-over-bms-and-celgene-merger-payout-as-fda-extends-drug-review/
FDA hastens development of Novartis’ Kymriah in follicular lymphomaNovartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah Share XFDA hastens development of Novartis’ Kymriah in follicular lymphomahttps://pharmaphorum.com/news/fda-hastens-development-of-novartis-kymriah-in-follicular-lymphoma/
BMS’ big merger bet is still on with latest CAR-T filingBristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final Share XBMS’ big merger bet is still on with latest CAR-T filinghttps://pharmaphorum.com/news/bms-and-bluebird-file-multiple-myeloma-car-t/
Gilead to buy immuno-oncology firm Forty Seven for $4.9bnGilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers Share XGilead to buy immuno-oncology firm Forty Seven for $4.9bnhttps://pharmaphorum.com/news/gilead-to-buy-immuno-oncology-firm-forty-seven-for-4-9bn/
FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlineSpeculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger Share XFDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlinehttps://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/
BMS files first drug from triple bet with Celgene shareholders with FDABristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” Share XBMS files first drug from triple bet with Celgene shareholders with FDAhttps://pharmaphorum.com/news/bms-files-first-drug-from-triple-bet-with-celgene-shareholders-with-fda/
Merck buys ArQule and BTK drug for $2.7bnMerck & Co. has announced it is to snap up ArQule for $2.7 billion, just as the US Share XMerck buys ArQule and BTK drug for $2.7bnhttps://pharmaphorum.com/news/merck-buys-arqule-for/
